Scarica l'app Stockscreener
69.45
1.77%
-1.25
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTCT Giù?
Forum
Previsione
Precedente Chiudi:
$70.70
Aprire:
$70.95
Volume 24 ore:
851.78K
Relative Volume:
0.56
Capitalizzazione di mercato:
$5.58B
Reddito:
$900.66M
Utile/perdita netta:
$-453.20M
Rapporto P/E:
-11.69
EPS:
-5.94
Flusso di cassa netto:
$-274.19M
1 W Prestazione:
-7.00%
1M Prestazione:
-7.89%
6M Prestazione:
+44.18%
1 anno Prestazione:
+39.82%
Intervallo 1D:
$69.30
$72.00
Intervallo di 1 settimana:
$69.30
$74.98
Portata 52W:
$35.95
$87.50
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Nome
Ptc Therapeutics Inc
Settore
Industria
Telefono
(908) 222-7000
Indirizzo
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
69.45 | 5.68B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2025-12-01 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-06-17 | Iniziato | Truist | Buy |
| 2025-05-09 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-05-07 | Aggiornamento | Citigroup | Sell → Neutral |
| 2025-03-11 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Iniziato | Scotiabank | Sector Perform |
| 2024-12-13 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-09-04 | Iniziato | Robert W. Baird | Outperform |
| 2024-08-26 | Ripresa | UBS | Buy |
| 2024-05-20 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-10-30 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Downgrade | Citigroup | Neutral → Sell |
| 2023-10-06 | Downgrade | Truist | Buy → Hold |
| 2023-09-18 | Downgrade | Citigroup | Buy → Neutral |
| 2023-09-15 | Downgrade | Raymond James | Outperform → Underperform |
| 2023-03-17 | Iniziato | SVB Securities | Market Perform |
| 2022-12-14 | Iniziato | Goldman | Sell |
| 2022-09-12 | Iniziato | Jefferies | Buy |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2022-04-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-03-29 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-01-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-11-30 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-10-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-04-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-02-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-02-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-05-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Iniziato | Bernstein | Outperform |
| 2018-10-03 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Iniziato | Credit Suisse | Outperform |
| 2018-06-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Downgrade | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Downgrade | JP Morgan | Neutral → Underweight |
Mostra tutto
Ptc Therapeutics Inc Borsa (PTCT) Ultime notizie
Will PTC Therapeutics Inc. benefit from current market trendsMarket Movement Recap & Short-Term High Return Ideas - mfd.ru
PTC Withdraws Translarna US FDA Filing - Citeline News & Insights
PTC Therapeutics Ends Bid to Seek FDA Approval for Rare Muscle Disease Drug - MedCity News
PTC Withdraws FDA Filing For Translarna - Citeline News & Insights
PTC Therapeutics withdraws Translarna NDA - The Pharma Letter
PTC Therapeutics Pulls Translarna Bid After FDA Flags Weak Proof - Benzinga
PTC Therapeutics Withdraws NDA Resubmission for Translarna Following FDA Feedback - marketscreener.com
PTC Therapeutics Withdraws Translarna NDA After FDA Feedback - TipRanks
PTC Therapeutics falls after withdrawing muscle disorder drug marketing application - TradingView
PTC Therapeutics stock falls after withdrawing Translarna drug application By Investing.com - Investing.com Canada
PTC Therapeutics Provides Regulatory Update on Translarna™ - Yahoo Finance
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Finviz
PTC Therapeutics (PTCT) Projected to Post Quarterly Earnings on Thursday - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Shareholders Have Earned a 18% CAGR Over the Last Three Years - 富途牛牛
PTC Therapeutics, Inc. (PTCT) Launches SUFIANCE for PKU - MSN
Price Action: How does Guardian Pharmacy Services Inc correlate with NasdaqTrade Risk Assessment & Safe Entry Point Alerts - baoquankhu1.vn
PTC Therapeutics Inc (NASDAQ:PTCT): A GARP Stock with Strong Growth and Moderate Valuation - ChartMill
PTC Therapeutics, Inc. $PTCT Stock Position Decreased by BI Asset Management Fondsmaeglerselskab A S - MarketBeat
Johnson & Johnson vs PTC Therapeutics: Which Stock Could Rally? - Trefis
PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026 - Finviz
Between PTC Therapeutics and Eli Lilly, Which Stock Looks Set to Break Out? - Trefis
PTC Therapeutics vs Merck: Which Is the Stronger Buy Today? - Trefis
Understanding Momentum Shifts in (PTCT) - Stock Traders Daily
Tech Rally: Is PTC Therapeutics Inc a stock for growth or value investorsJuly 2025 EndofMonth & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
WCM Investment Management LLC Acquires Shares of 147,065 PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics (PTCT) Investor Outlook: An 18% Upside Potential Amidst Robust Pipeline - DirectorsTalk Interviews
PTCT SEC FilingsPtc Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
PTC Therapeutics Inc (NASDAQ:PTCT) Combines High-Growth Momentum with Bullish Technical Setup - ChartMill
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Meme Stocks: What is PTC Therapeutics Inc.’s book value per shareEarnings Overview Summary & Growth Focused Entry Reports - baoquankhu1.vn
Evaluating PTC Therapeutics (PTCT) Valuation After Barclays Rating Upgrade And Growing Analyst Confidence - Yahoo Finance
Converging Analyst Upgrades on PTC’s Rare Disease Pipeline Might Change The Case For Investing In PTC Therapeutics (PTCT) - Sahm
Barclays Upgrades PTC Therapeutics (PTCT) - Nasdaq
PTC Therapeutics (PTCT) Sees Analyst Rating Upgrade to Overweigh - GuruFocus
PTC Therapeutics stock initiated with Overweight rating at Barclays By Investing.com - Investing.com Canada
PTC Therapeutics, Inc. (PTCT) Stock Analysis: Potential Upside with Innovative Rare Disorder Treatments - DirectorsTalk Interviews
A Look At PTC Therapeutics (PTCT) Valuation After New 2026 Revenue Guidance And Morgan Stanley Support - Sahm
Sector Gamma AS Increases Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
Avoiding Lag: Real-Time Signals in (PTCT) Movement - Stock Traders Daily
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Morgan Stanley Is Bullish on PTC Therapeutics, Inc. (PTCT) as Small-Cap Biotech Outlook Improves - Finviz
QRG Capital Management Inc. Takes Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
Momentum Shift: What is International Money Express Incs market positionTrade Exit Report & AI Optimized Trading Strategy Guides - baoquankhu1.vn
First Week of September 18th Options Trading For PTC Therapeutics - Nasdaq
Does 2026 Revenue Guidance And Sephience Momentum Change The Bull Case For PTC Therapeutics (PTCT)? - Sahm
Discipline and Rules-Based Execution in PTCT Response - Stock Traders Daily
PTC Therapeutics projects FY26 product revenue between $700M to $800M - MSN
PTC Therapeutics reports $92.5M in Q4 Sephience revenue By Investing.com - Investing.com Nigeria
Lobbying Update: $50,000 of PTC THERAPEUTICS INC. lobbying was just disclosed - Quiver Quantitative
Ptc Therapeutics CEO Klein sells $192k in shares By Investing.com - Investing.com Nigeria
Ptc Therapeutics CEO Klein sells $192k in shares - Investing.com
Ptc Therapeutics Inc Azioni (PTCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):